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BACKGROUND: In various tumour types, elevated expression of the X-linked inhibitor of apoptosis protein (XIAP) has been observed
and XIAP targeting in diverse tumour entities enhanced the susceptibility to chemotherapeutic agents. Therefore, XIAP has been
described and reviewed repeatedly as a chemoresistance factor in different tumour entities. However, rather than being an adverse
prognostic marker, recent data suggest that elevated XIAP expression may be associated with a favourable clinical outcome. These
somewhat conflicting findings, and the fact that in early studies XIAP suppressed apoptosis only when expressed transiently at levels
far in excess of its physiological concentration, argue that the function of XIAP as an anti-apoptotic factor in tumour cells is both more
complex and diverse than previously appreciated.
METHODS: To better understand the impact of long-term elevated XIAP expression on resistance to chemotherapy, we generated cell
lines stably overexpressing XIAP. The role of mitochondria was examined by stable expression of Bcl2 or stable knockdown of
second mitochondria-derived activator of caspase (SMAC) in combination with up- or downregulation of XIAP expression.
RESULTS: Our data show that long-term expression of XIAP at concentrations comparable to that in tumour cells (two- to five-fold
increase) resulted in little or no resistance towards chemotherapeutic drugs. The XIAP overexpression only in conjunction with stable
knockdown of a single XIAP-antagonising factor such as SMAC resulted in severe resistance to cytostatic agents demonstrating XIAP
as a potent chemoresistance factor only in cells lacking functional XIAP regulatory circuits.
CONCLUSION: Our results demonstrated that elevated XIAP expression alone cannot serve as a predictive marker of chemoresistance.
Our data suggest that in order to predict the impact of XIAP on chemosusceptibility for a given tumour entity, the expression levels
and functional states of all XIAP modulators need to be taken into account.
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Each step of the apoptotic signalling cascade is under stringent
control. Apoptotic signalling can be regulated at the apical point of
the apoptotic cascade by controlling the translation of death-
inducing signals into proteolytic activation or more critically by
direct modulation of the proteolytic activity of caspases. The later
is modulated by direct interaction of caspases with the X-linked
inhibitor of apoptosis protein (XIAP). The XIAP is the only cellular
protein that has evolved to potently inhibit the enzymatic activity
of mammalian caspases at both the initiation phase (casp-9) and
the execution phase (casp-3 and -7) of apoptosis (Deveraux et al,
1997). The anti-apoptotic activity of XIAP is in turn controlled by
the so-called second mitochondria-derived activator of caspases
(SMACs), which inhibits XIAP by direct binding (Vaux and Silke,
2003). The SMAC is a mitochondrial protein that is released during
apoptosis along with cytochrome c (cyt c) and other mitochondrial
apoptogenic factors. Once in the cytosol, SMAC binds to XIAP and
disrupts its caspase-inhibiting activity thereby restoring the
apoptotic machinery.
Since the discovery of XIAP in the second half of the 1990s, our
understanding of this unique IAP has progressed rapidly,
including a detailed structural and mechanistic view of its activity
in addition to abundant cell biological data (Eckelman et al, 2006).
According to this data, XIAP is thought to render tumour cells
resistant to multi-agent chemotherapy through its ability to inhibit
caspases, and, on this basis, has been proposed as an important
adverse prognostic factor responsible for tumour chemoresistance
(Schimmer et al, 2006). At odds with these findings, however,
elevated XIAP expression has recently been shown to be associated
with a favourable clinical outcome (Ferreira et al, 2001; Seligson
et al, 2007; Hwang et al, 2008).
The critical point in determining the precise role of XIAP in
drug resistance besides its expression level is the degree and
involvement of cellular regulatory circuits directly or indirectly
controlling XIAP function. Indeed, in the initial investigations,
XIAP was capable of suppressing apoptosis only when transiently
expressed at levels far in excess of physiological values and
disregarding the mitochondrial check points representing
the central regulatory machinery in controlling XIAP action
(Srinivasula and Ashwell, 2008). The physiological relevance of
these observations is therefore limited. To better understand the
impact of long-term elevated XIAP expression on resistance to
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schemotherapy, we generated cell lines stably expressing XIAP. The
role of mitochondria was examined by the stable expression of
Bcl2 or stable knockdown of SMAC in combination with up- or
downregulation of XIAP expression. Our data show that increased
XIAP expression alone does not induce chemoresistance and that
the anti-apoptotic function of XIAP is secondary to defective
mitochondrial responses to apoptotic stimuli.
MATERIALS AND METHODS
Cell lines and cell culture
HeLa, HeLa-Bcl2, and HeLa-mycXIAP (Kashkar et al, 2005, 2007)
cell lines were cultured in DMEM supplemented with 10% foetal
calf serum, 2mML -glutamine, 100mgml
1 streptomycin, and
100unitsml
1 penicillin (Biochrom, Berlin, Germany). Cytostatic
agents were purchased from Sigma (Deisenhofen, Germany),
except for staurosporine (STS) (Alexis, Lausen, Switzerland).
Caspase activity was blocked by co-treatment of cells with 20mM
Z-VAD(Ome)-FMK (Alexis, Gru ¨nberg, Germany).
Sample preparation, immunoblotting, and
immunoprecipitation
Whole-cell extracts were prepared by cell lysis in CHAPS buffer.
Poly(ADP-ribose) polymerase (PARP) cleavage was assessed after
incubation of pellets in urea-extraction buffer. Cytosolic extracts
were prepared in buffer A as described. Rabbit polyclonal
antiserum for human Bax and mouse monoclonal antibodies for
XIAP, Bcl2, PARP, active Bax (clone 6A7), and cyt c were from BD
Laboratories (Heidelberg, Germany); mouse anti-SMAC antibody
was from Cell Signalling Technology (Beverly, MA, USA). Active
Bax was detected with anti-Bax antibody (clone 6A7) (Kashkar
et al, 2002, 2005).
siRNA and lentiviral gene transfer
The pLenti6/V5DEST XIAPshRNA–, SMACshRNA–, or
scrshRNA-expressing vectors was created using LR recombination
(ViraPower Lentiviral expression system, Invitrogen, Karlsruhe,
Germany). Stable cell lines were generated by blasticidin selection
(Invitrogen) as described (Kashkar et al, 2006).
Cell viability
Cells (10
4 per well) were incubated in 96-well plates with cytostatic
agents as indicated. Cell viability was assessed by the XTT test (Cell
Proliferation Kit II, Roche Applied Sciences, Mannheim, Germany) or
crystal violet assay system (CVS). For XTT, absorbance was measured
with an ELISA reader (at 450nm; reference at 620nm). For CVS, cells
were washed in PBS, stained with crystal violet (0.2% w/v in
2% EtOH), and dissolved in 0.2 M sodium citrate and 100% EtOH
(1:1 v/v). The colorimetric measurement was carried out at 595nm
(Tecan GENious Pro; ThermoFischer Scientific, Langenselbold,
Germany). Data are means of at least three different experiments in
triplicate. Blank absorbance was subtracted from the samples, and the
difference was expressed as ‘% cell viability’ (100% in untreated cells).
Clonogenicity was determined as described (Vogler et al,2 0 0 7 ) .
RESULTS
Elevated XIAP expression does not confer chemoresistance
To characterise the role of XIAP as a chemoresistance factor,
a HeLa cell line stably expressing myc-tagged XIAP (mycXIAP)
was established (Figure 1A). The cytoprotective potency of XIAP
was evaluated in the HeLa-mycXIAP cell line after treatment
with chemotherapeutic agents, including STS, doxorubicin (DOX),
etoposide (ETO), mitoxantrone (MTO), vinblastine (VBL), and
vincristine (VCR), and compared to unmodified HeLa cells as well
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Figure 1 Cytostatic agent-induced cell death. (A) X-linked inhibitor of apoptosis protein (XIAP), actin, Bcl2, second mitochondria-derived activator of
caspase (SMAC), and cytochrome c (cyt c) were detected in total cell extracts of HeLa, HeLa-mycXIAP, and HeLa-Bcl2 by western blotting. (B and C)
HeLa, HeLa-mycXIAP, and HeLa-Bcl2 cell lines were treated for 24h with staurosporine (STS, 0.5mM), doxorubicin (DOX, 5mM), etoposide (ETO, 100mM),
mitoxantrone (MTO, 5mM), vinblastine (VBL, 50nM), and vincristine (VCR, 50nM). Viability was assessed by crystal violet staining (CVS). Poly(ADP-ribose)
polymerase (PARP) cleavage was detected in nuclear extracts using mouse anti-PARP antibody (C). *Indicates nonspecific bands recognised by anti-XIAP
antibody. IB, immunoblotting.
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sas a HeLa cell line stably expressing Bcl2 (HeLa-Bcl2) as an
established chemoresistance factor (Reed, 1995; Kashkar et al,
2005; Letai, 2008) (Figure 1A). Unexpectedly, XIAP expression had
no cytoprotective effect nor did XIAP expression confer an anti-
apoptotic effect towards cytostatic agents (Figure 1B and C). All
cytostatic agents exerted comparable cytotoxic effects in HeLa and
HeLa-mycXIAP cell lines in various cytotoxicity assays including
CVS (Figure 1B), XTT, trypan blue exclusion, and clonogenicity
assays (Supplementary Figure S1). Cleavage of PARP was analysed
to monitor the ongoing apoptotic process and to demonstrate
a functional apoptotic cascade in HeLa and HeLa-mycXIAP cell
lines upon cytostatic treatments (Figure 1C). In contrast to XIAP
expression, stable Bcl2 expression completely abrogated the
apoptotic capability of cells in response to cytostatic drugs
(Figure 1B and C and Supplementary Figure S1).
Caspase-independent mitochondrial SMAC release in
response to cytostatic agents diminishes the anti-apoptotic
potential of XIAP
To investigate the inhibitory potency of stably expressed XIAP on
caspase activity in the HeLa-mycXIAP cell line, cytosolic extracts
of intact HeLa cells were prepared and caspase activity was
initiated by exogenously added cyt c and dATP (Kashkar et al,
2003). In contrast to the parental HeLa cells, casp-3 activity was
significantly impaired in cytosolic extracts derived from HeLa-
mycXIAP cells, demonstrating the caspase inhibitory potency of
stably expressed mycXIAP. As the sensory centres of cytotoxic
stresses, the mitochondria promote caspase activity by releasing
pro-apoptotic factors, including cyt c and SMAC. Once released
into the cytosol, SMAC interacts with XIAP to release XIAP-
mediated inhibition of casp-3. Accordingly, in cytosolic extracts of
HeLa and HeLa-mycXIAP cells, addition of the synthetic SMAC
agonist (N7 peptide) enhanced casp-3 activity initiated by cyt
c/dATP (Figure 2A). Detailed analyses of the mitochondrial
apoptotic pathway in HeLa, HeLa-mycXIAP, and HeLa-Bcl2 cell
lines showed that all tested cytostatic agents were capable of
initiating the mitochondrial release of cyt c and SMAC in HeLa and
HeLa-mycXIAP cells, but not in the HeLa-Bcl2 cells with blocked
mitochondria (Figure 2B). The release of the mitochondrial
pro-apoptotic factors in response to cytostatic drug treatment
was predominantly a caspase-independent process as demon-
strated by pretreatment with the universal caspase inhibitor z-VAD
(Figure 2B). In contrast to Bcl2, XIAP was not able to prevent
the cytostatic agent-induced mitochondrial release of SMAC
(Figure 2B).
If, indeed, the mitochondrial release of SMAC was responsible
for the neutralisation of XIAP, then downregulation of SMAC
should restore the caspase-inhibitory function of XIAP and
increase resistance towards cytostatic agents. To address this
issue, we stably downregulated SMAC expression using small
hairpin RNA (shRNA) targeting SMAC mRNA (Kashkar et al,
2006) (Figure 3A). As expected, HeLa-SMACshRNA cells showed
a markedly reduced susceptibility to chemotherapeutic treat-
ments compared with their parental counterparts, HeLa and HeLa-
mycXIAP, and this was even more pronounced in the presence of
XIAP overexpression shown in HeLa-mycXIAP-SMACshRNA cells
(Figure 3B and Supplementary Figure S2). Altogether, these data
demonstrate a regulatory role of SMAC during cytostatic agent-
induced cell death. Importantly, the SMAC knockdown did not
cause any changes in cyt c release after cytostatic drug treatment
that could account for the reduced apoptotic activity (Figure 4).
Rather, the knockdown of SMAC in HeLa-SMACshRNA cells
resulted in the blockade of caspase activity as illustrated by incom-
plete PARP cleavage (Figure 4A and Supplementary Figure S3)
and a failure of nuclear fragmentation (Figure 4B). Inhibition
of caspase activity was more pronounced in XIAP-expressing
HeLa-mycXIAP-SMACshRNA cells as shown by complete blockade
of PARP cleavage (Figure 4A and Supplementary Figure S3).
The antagonistic action of SMAC and XIAP was confirmed
by XIAP knockdown in HeLa-SMACshRNA cells (Figure 5).
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Figure 2 Cytostatic agents induce caspase-independent second
mitochondria-derived activator of caspase (SMAC) release. (A) Cytosolic
extracts of HeLa and HeLa-mycXIAP cells were prepared by incubating
with increasing amount of cytochrome c (cyt c; 0, 0.25, 0.5, and 1mM) and
dATP with or without SMAC N7 peptide for 15min at 301C. Relative
casp-3 activity was measured using 100mM Ac-DEVD-AFC as arbitrary
units. Values represent means±s.d. from at least three experiments in
triplicate. (B) HeLa, HeLa-mycXIAP, and HeLa-Bcl2 cells (all 10
6) were
treated with staurosporine (STS; 0, 0.25, and 0.5mM), doxorubicin (DOX;
0, 2, and 5mM), etoposide (ETO; 0, 10, and 50mM), mitoxantrone (MTO; 0,
1, and 5mM), vinblastine (VBL; 0, 5, and 20nM), and vincristine (VCR; 0, 5,
and 20nM) for 12h. SMAC and cyt c were detected in cytosolic extracts by
western blotting. Actin was served as loading control. Caspase activity in
cytostatic drug-induced cytchrome c/SMAC release was examined in HeLa
cells by z-VAD-FMK (20mM) co-treatment. IB, immunoblotting.
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sHeLa-SMACshRNA cells were transiently transfected with DNA
constructs containing XIAPshRNA or scrshRNA expression
cassettes in addition to co-expressing EGFP to visualise the
transfected cells (Figure 5A). Immunofluorescence analysis
revealed nuclear fragmentation as a sign of the ongoing apoptotic
process after STS treatment in HeLa-SMACshRNA cells transiently
transfected with EGFP-XIAPshRNA, but not in untransfected cells
or cells transfected with EGFP-scr-RNA (Figure 5B). Correspond-
ingly, the viability of HeLa-SMACshRNA cells depleted of XIAP
was also reduced in response to STS or DOX treatments
(Figure 5C). It is important to note that chemoresistance caused
by loss of SMAC expression was only reversed when XIAP was
downregulated, but not by knockdown of other members of the
IAP protein family such as cIAP1 and cIAP2 (Supplementary
Figure S4). Altogether, these data demonstrate the specific
interplay between XIAP and SMAC in modulating caspase activity
and determining the drug-resistant phenotype.
DISCUSSION
As a prominent member of the IAP protein family with the most
potent caspase inhibitory capacity (Eckelman et al, 2006), XIAP, is
regarded as a powerful chemoresistance factor. However, in the
initial investigations, using transient overexpression systems,
XIAP was capable of suppressing apoptosis only at levels far in
excess of its physiological concentrations. Since then, XIAP has
also been shown to be crucially involved in several non-apoptotic
signalling cascades. Therefore, its description as ‘X-linked
inhibitor of apoptosis’ has recently been called into question,
suggesting that the anti-apoptotic functions ascribed to XIAP may
not reflect the true nature of its normal biological activities
(O’Riordan et al, 2008; Srinivasula and Ashwell, 2008). In
agreement with this, long-term expression of XIAP at concentra-
tions comparable to that in tumour cells (two- to five-fold
increase) (Kashkar et al, 2003) resulted in little or no resistance
towards chemotherapeutic drugs (Figure 1).
Several factors including SMAC, Omi, XAF1 (XIAP-associated
factor 1), and several IAP-binding motif (IBM)-containing proteins,
including polypeptide chain-releasing factor (GSPT1) and Check-
point kinase 1 (Chk1), have critical roles in controlling XIAP
functions (LaCasse et al, 2008; Srinivasula and Ashwell, 2008).
However, previous studies describing the function of XIAP in
cell-free systems using recombinant proteins (Deveraux et al,1 9 9 7 ,
1998), yeast models (Silke et al, 2001, 2002), or transient-over-
expression studies in intact cells (Deveraux et al,1 9 9 8 ;S i l k eet al,
2001) have disregarded the cellular regulatory mechanisms control-
ling XIAP function. Strikingly, here we show that stable knockdown
of a single XIAP-antagonising factor such as SMAC resulted in
severe resistance to cytostatic agents on XIAP overexpression
(Figures 2–5), demonstrating XIAP as a potent chemoresistance
factor in cells lacking functional XIAP regulatory circuits.
Interestingly, several recent studies failed to demonstrate a
correlation between XIAP expression and clinical outcomes,
although some reported an association between XIAP expression
and favourable clinical outcomes (Ferreira et al, 2001; Liu et al,
2001; Carter et al, 2003; Seligson et al, 2007; Hwang et al, 2008).
Our data suggest that, in order to predict the impact of XIAP on
chemosusceptibility for a given tumour entity, the expression
levels and functional states of all XIAP modulators need to be
taken into account. That the finely tuned balance between XIAP
and its antagonists is critical in determining the clinical outcome
in cancer patients was demonstrated in an analysis of 187 gastric
adenocarcinomas in which the expression levels of XIAP and its
antagonising factors including SMAC and XAF1 were examined.
The XIAP, SMAC, and XAF1 individually were not associated with
disease-specific survival. However, patients showing high expres-
sion levels of XIAP and low expression of XAF1 had significantly
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Figure 3 Knockdown of second mitochondria-derived activator of
caspase (SMAC) promotes resistance to cytostatic agents and facilitates
anti-apoptotic function of X-linked inhibitor of apoptosis protein (XIAP).
(A) XIAP, actin, SMAC, and cytochrome c (cyt c) were detected in total
cell extracts of HeLa, HeLa-SMACshRNA, HeLa-mycXIAP, and HeLa-
mycXIAP-SMACshRNA cells by western blotting for XIAP, cyt c, actin
(reprobed and merged), and SMAC (reprobed and merged). (B) Cells
were treated for 24h with staurosporine (STS, 0.5mM), doxorubicin (DOX,
5mM), etoposide (ETO, 100mM), mitoxantrone (MTO, 5mM), vinblastine
(VBL, 50nM), and vincristine (VCR, 50nM). The percentage of viable cells
was determined by crystal violet staining (CVS) and cell death by trypan
blue exclusion. Values represent means±s.d. of at least three experiments
carried out in triplicate. *Indicates nonspecific bands recognised by
anti-XIAP antibody. IB, immunoblotting.
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spoorer survival when compared with other groups (Shibata et al,
2008). Together these data suggest that XIAP-targeting drugs could
be particularly effective in tumours in which XIAP function is
unopposed because the regulatory mechanisms are inactivated.
Such tumour targets are already known, including Hodgkin’s
lymphoma, CLL, and melanoma. The use of SMAC mimetics to
sensitise such malignancies for chemotherapy offers an exciting
new treatment option.
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